Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00999791 |
Recruitment Status
: Unknown
Verified October 2009 by Shahid Beheshti University of Medical Sciences.
Recruitment status was: Recruiting
First Posted
: October 22, 2009
Last Update Posted
: May 4, 2010
|
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | July 7, 2009 | ||
First Posted Date ICMJE | October 22, 2009 | ||
Last Update Posted Date | May 4, 2010 | ||
Study Start Date ICMJE | July 2009 | ||
Primary Completion Date | Not Provided | ||
Current Primary Outcome Measures ICMJE | Not Provided | ||
Original Primary Outcome Measures ICMJE | Not Provided | ||
Change History | Complete list of historical versions of study NCT00999791 on ClinicalTrials.gov Archive Site | ||
Current Secondary Outcome Measures ICMJE | Not Provided | ||
Original Secondary Outcome Measures ICMJE | Not Provided | ||
Current Other Outcome Measures ICMJE | Not Provided | ||
Original Other Outcome Measures ICMJE | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema | ||
Official Title ICMJE | Not Provided | ||
Brief Summary | Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema. |
||
Detailed Description | Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse diabetic macular edema for treatment. in this study, we are going to compare the effect of intra vitreal injection of Diclofenac and Bevacizumab in primary treatment of diffuse diabetic macular edema. |
||
Study Type ICMJE | Interventional | ||
Study Phase | Phase 1 | ||
Study Design ICMJE | Intervention Model: Parallel Assignment Primary Purpose: Treatment |
||
Condition ICMJE | Diffuse Diabetic Macular Edema | ||
Intervention ICMJE |
|
||
Study Arms |
|
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Unknown status | ||
Enrollment ICMJE | Not Provided | ||
Original Enrollment ICMJE | Not Provided | ||
Study Completion Date | Not Provided | ||
Primary Completion Date | Not Provided | ||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | Child, Adult, Senior | ||
Accepts Healthy Volunteers | Not Provided | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | Iran, Islamic Republic of | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT00999791 | ||
Other Study ID Numbers ICMJE | 8818 | ||
Has Data Monitoring Committee | Yes | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | Not Provided | ||
Study Sponsor ICMJE | Shahid Beheshti University of Medical Sciences | ||
Collaborators ICMJE | Not Provided | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Shahid Beheshti University of Medical Sciences | ||
Verification Date | October 2009 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |